培训研讨会 | 24th Annual Discovery on Target 2026 官方网站

training-seminars-header

Cambridge Healthtech Institute的培训研讨会提供涵盖了广泛的学术理论及其背景，以及现实生活中的案例研究和所面临的挑战及适用的解决方案资讯。每个培训研讨会都结合了正式讲座与互动讨论和活动，以让学习成果最大化。以熟练的讲师来主持培训研讨会，以适用于当前研究的内容，并为该领域的初学者提供重要指导。以目前研究的内容为焦点，提供针对在该领域的初学者重要的指南。

培训研讨会仅限面对面实体会议。

Monday, September 28, 2026 9:00 am - 6:00 pm

TS3A: AI-Driven Design of Biologics: State-of-the-Art ML Models & Real-World Applications

Artificial intelligence has driven remarkable breakthroughs in structure prediction, sequence design, and protein engineering. This course equips researchers - from those seeking a first foothold in the field to practitioners looking for deeper insight into emerging models and their application - with a rigorous, grounded understanding of foundational tools including AlphaFold, Boltz, ImmuneBuilder, ESM, AntiBERTy, ProteinMPNN, and RFDiffusion, as well as emerging pipelines such as BindCraft, RFAntibody and BoltzGen. Three building sessions move from foundational principles to real-world application, examining where the models come from, model selection and thoughtful application, and how performance benchmarks hold up - or don't - in active discovery pipelines.

Session 1: Foundations

Origins and evolution of AI protein models: from early sequence models to modern structure-based diffusion approaches
Understanding training data: sources, biases, and implications for model generalizability with best practices for model selection

Session 2: Using AI Models

AI model selection and thoughtful application, with discussion of inputs and outputs
The role of the oracle in generative AI protein design

Session 3: Real-World Applications

Benchmarked performance vs. real-world biologics discovery: navigating the gap
In silico selection metrics, sampling strategies, and translating computational results to the lab

INSTRUCTOR BIOGRAPHY:

David P. Nannemann, PhD, Vice President, Rosetta Commons Foundation

David is an expert in protein engineering and computational design, with extensive experience applying AI-driven modeling tools in an industry setting. He serves as Vice President of the Rosetta Commons Foundation and Industry Chair on the Rosetta Commons board, helping bridge academic advancements with industry applications. As Managing Member of Rosetta Design Group, he collaborates with companies of all sizes to tackle complex challenges in biologics design. David's deep expertise in leveraging cutting-edge tools like Rosetta, AlphaFold, and diffusion-based models for protein design make him an invaluable guide for participants looking to apply AI-driven biologics design in real-world settings.

TS4A: The End Game: From Lead Optimization to Drug Candidate Selection

Drugs interact with complex physiology to give different activities under different conditions. The discovery candidate selection process must demonstrate these different activities in anticipation of therapeutic outcomes; failure at this stage is the most costly and the translation of drug activity to human pathophysiology is a notorious graveyard for projects. Pharmacology is the unique discipline to prevent this. This course will take registrants through the unique aspects of Pharmacologic analysis of drug-target interaction to convert descriptive data (what we see) to predictive data (what will be seen in other systems). Data from a range of candidate targets (GPCRs, ion channels, enzymes) and ligands (small molecules, biologics, allosterics) will be used to demonstrate the techniques Pharmacology has to offer to quantify drug potency, efficacy and modulatory activity in a variety of settings. In addition to discussion of techniques, a series of case histories will be used to illustrate the concepts.

Detailed Agenda
Session 1 (9:00-11:00 am)

Introduction to candidate selection
Some unique features of pharmacology as a discipline
The drug discovery landscape and discovery infrastructure
Pharmacologic assays: The Eyes to See
Pharmacologic tools: The Dose-Response Curve

Session 2 (1:30-3:30 pm)

Determining mechanism of action
Ligand affinity
Ligand efficacy
Allosteric protein function

Session 3 (4:00-6:00 pm)

Pharmacokinetics for discovery
Early safety studies
In Vivo residence time and kinetics
The Endgame: case studies

INSTRUCTOR BIOGRAPHY:

Terrence P. Kenakin, PhD, Professor, Pharmacology, University of North Carolina at Chapel Hill

Beginning his career as a synthetic chemist, Terry Kenakin received a PhD in Pharmacology at the University of Alberta in Canada. After a postdoctoral fellowship at University College London, UK, he joined Burroughs-Wellcome as an associate scientist for 7 years. From there, he continued working in drug discovery for 25 years first at Glaxo, Inc., then Glaxo Wellcome, and finally as a Director at GlaxoSmithKline Research and Development Laboratories at Research Triangle Park, North Carolina, USA. Dr. Kenakin is now a professor in the Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill. Currently he is engaged in studies aimed at the optimal design of drug activity assays systems, the discovery and testing of allosteric molecules for therapeutic application, and the quantitative modeling of drug effects. In addition, he is Director of the Pharmacology graduate courses at the UNC School of Medicine. He is a member of numerous editorial boards, as well as Editor-in-Chief of the Journal of Receptors and Signal Transduction. He has authored numerous articles and has written 10 books on pharmacology.

* 活动内容有可能不事先告知作更动及调整。

Choose your language